Investornewsbreaks Processa Pharmaceuticals Inc. (NASDAQ: P...| MENAFN.COM

Thursday, 18 August 2022 02:28 GMT

Investornewsbreaks Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Launches New Website Focused On Rare Disease


(MENAFN- Investor Brand Network)

Processa Pharmaceuticals (NASDAQ: PCSA) , a clinical-stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient's survival and/or quality of life, has released a new website: Necrobiosislipoidicastudy.com. Through the new website, the company is working to increase awareness of ulcerative Necrobiosis Lipoidica (“uNL”), an extremely rare condition, and to inform patients about its ongoing phase 2 study, which is evaluating the use of PCSA's proprietary PCS499 for the treatment of this rare condition. According to the announcement, Necrobiosis Lipoidica (“NL”) is a chronic skin condition affecting anywhere from 22,000 to 55,000 in the United States, and currently, there is no treatment for the condition that has been approved by the U.S. Food and Drug Administration (“FDA”). About one-third of the time, the skin condition develops into ulcerated lesions that can cause life-threatening infections and necrosis. PCSA's randomized, double-blind, placebo-controlled study is designed to assess the efficacy and safety of PCS499 for the treatment of ulcerations of patients with NL.“For patients with NL, the tissue below the skin can become necrotic forming open ulcers which can last from months to years with complications such as infections, amputation and cancer,” said Pharm D chief development officer Sian Bigora in the press release.“Currently there is no FDA-approved treatment for uNL or NL, no standard of care, and the treatments that are used are generally inadequate. We are conducting the Phase 2b study to hopefully show that PCS499 can be an option for these patients who currently have little to no options available.”

To view the full press release, visit 

About Processa Pharmaceuticals Inc.

The mission of Processa is to develop products with existing clinical evidence of efficacy for patients with unmet or underserved medical conditions who need treatment options that improve survival and/or quality of life. The company uses these criteria for selection to further develop its pipeline programs to achieve high-value milestones effectively and efficiently. Active clinical pipeline programs include PCS6422 (“PCS6422”), a metastatic colorectal cancer and breast cancer program; PCS499 (“PCS499”), an ulcerative necrobiosis lipoidica program; and PCS12852 (“PCS12852”), a gastroparesis program. The members of the Processa development team have been involved with more than 30 drug approvals by the FDA, including drug products targeted to orphan disease conditions, and more than 100 FDA meetings throughout their careers. For more information, visit the company's website at  . 

NOTE TO INVESTORS: The latest news and updates relating to PCSA are available in the company's newsroom at 

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you'll need to ensure that your next press release grabs the attention of your target audience and doesn't let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire's syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit 

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: 

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office

InvestorWire is part of the InvestorBrandNetwork .

MENAFN04082022000224011066ID1104647674


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.